Briahna Joy Gray and Robby Soave react to reporting that Moderna and Pfizer will be conducting trials to determine whether there are long-term myocarditis risks linked to the covid vaccine. #Covid #moderna #pfizer
In April 2021, increased cases of myocarditis and pericarditis were reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna). Data from multiple studies show a rare risk for myocarditis and/or pericarditis following receipt of mRNA COVID-19 vaccines. These rare cases of myocarditis or pericarditis have occurred most frequently in adolescent and young adult males, ages 16 years and older, within 7 days after receiving the second dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna). There has not been a similar reporting pattern observed after receipt of the Janssen COVID-19 Vaccine (Johnson & Johnson).
The CDC continues to recommend COVID-19 vaccination for everyone 6 months of age and older. The Advisory Committee on Immunization Practices (ACIP) and CDC have determined that the benefits (such as prevention of COVID-19 cases and its severe outcomes) outweigh the risks of myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines.
Rising is a weekday morning show with bipartisan hosts that breaks the mold of morning TV by taking viewers inside the halls of Washington power like never before. The show leans into the day’s political cycle with cutting edge analysis from DC insiders who can predict what is going to happen. It also sets the day’s political agenda by breaking exclusive news with a team of scoop-driven reporters and demanding answers during interviews with the country’s most important political newsmakers.
Follow Rising on social media: